Teva Pharmaceutical Industries (TEVA) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free TEVA Stock Alerts $16.93 +0.03 (+0.18%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 7:23 AM | marketbeat.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Hsbc Holdings PLCHsbc Holdings PLC increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 242.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,597,178 shares of tJune 2 at 3:58 AM | americanbankingnews.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 2 at 2:14 AM | americanbankingnews.comFY2025 EPS Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA) Boosted by Zacks ResearchJune 1 at 2:25 PM | businesswire.comNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)June 1 at 2:20 PM | businesswire.comTeva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024June 1 at 7:23 AM | marketbeat.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Allianz Asset Management GmbHAllianz Asset Management GmbH lessened its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 27.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,102,814 shares of the company'sMay 31 at 8:58 AM | marketbeat.comTeva Pharmaceutical Industries Limited Expected to Earn FY2025 Earnings of $2.51 Per Share (NYSE:TEVA)Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Equities researchers at Zacks Research upped their FY2025 EPS estimates for Teva Pharmaceutical Industries in a research note issued on Wednesday, May 29th. Zacks Research analyst R. Department now forecasts that the company willMay 31 at 7:02 AM | marketbeat.com2 Generic Drug Makers With Growing RunwaysBrand-name drug costs continue to climb, but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. Generics are loved by health insurers, Medicare, and patients as they contain the same compounds and active ingredients for a cheaper price.May 31 at 7:00 AM | marketbeat.com2 Generic Drug Makers With Growing RunwaysBrand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out.May 31 at 5:00 AM | americanbankingnews.comTeva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $21.00 at Bank of AmericaMay 31 at 1:24 AM | americanbankingnews.comQ2 2024 EPS Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA) Lowered by AnalystMay 30 at 12:20 PM | marketbeat.comBank of America Boosts Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $21.00Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday.May 30 at 5:41 AM | marketbeat.comZacks Research Equities Analysts Reduce Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Equities research analysts at Zacks Research decreased their Q2 2024 EPS estimates for Teva Pharmaceutical Industries in a research note issued on Wednesday, May 29th. Zacks Research analyst R. Department now anticipates that theMay 25, 2024 | marketbeat.comAbrams Capital Management L.P. Sells 1,969,597 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)Abrams Capital Management L.P. reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 24.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,996,836 shares of the compaMay 21, 2024 | msn.comTeva, Alvotech launch biosimilar against AbbVie’s HumiraMay 21, 2024 | marketbeat.comStockNews.com Lowers Teva Pharmaceutical Industries (NYSE:TEVA) to BuyStockNews.com downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Monday.May 20, 2024 | markets.businessinsider.comTeva Says Simlandi Injection Now Available In U.S.May 20, 2024 | marketbeat.comTraders Buy Large Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) was the recipient of some unusual options trading activity on Monday. Stock traders bought 42,625 call options on the stock. This is an increase of approximately 52% compared to the typical daily volume of 27,996 call options.May 19, 2024 | insidertrades.comAmir Weiss Sells 15,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) StockMay 18, 2024 | marketbeat.comPanagora Asset Management Inc. Acquires 374,561 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)Panagora Asset Management Inc. increased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 305.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 497,202 shares of the compMay 17, 2024 | insidertrades.comVikki L. Conway Sells 15,219 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) StockMay 16, 2024 | marketbeat.comBNP Paribas Financial Markets Boosts Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)BNP Paribas Financial Markets lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 22.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,425,984 shares of the compMay 16, 2024 | investorplace.comPatent Peril: 3 Stocks at Risk From the FTC's Drug CrusadeMay 16, 2024 | forbes.comChaco Vs. Teva: Which Adventure Sandal Is Right For You?May 15, 2024 | businesswire.comTeva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global OperationsMay 15, 2024 | marketbeat.comTeacher Retirement System of Texas Trims Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)Teacher Retirement System of Texas lowered its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 12.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 341,487 shMay 14, 2024 | finance.yahoo.comDavid Abrams Exits Teva Pharmaceutical in Q1 2024, Reflecting Strategic Portfolio AdjustmentsMay 14, 2024 | seekingalpha.comTeva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript)May 14, 2024 | marketbeat.comTeva Pharmaceutical Industries (NYSE:TEVA) Sets New 52-Week High at $17.09Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 1-Year High at $17.09May 13, 2024 | marketbeat.comTeva Pharmaceutical Industries' (TEVA) "Overweight" Rating Reaffirmed at Piper SandlerPiper Sandler reiterated an "overweight" rating and issued a $20.00 price target (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday.May 11, 2024 | marketbeat.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Stake Decreased by Monaco Asset Management SAMMonaco Asset Management SAM reduced its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 10.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,367,300 shares of tMay 11, 2024 | marketbeat.comTeva Pharmaceutical Industries (NYSE:TEVA) Rating Lowered to Buy at StockNews.comStockNews.com downgraded Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Friday.May 10, 2024 | marketbeat.comThese 7 Stocks Surged Double-Digits and Have Double-Digits to GoEarnings reports often catalyze big moves in a stock's price; the bigger the move, the more conviction the market shows. Catalysts for these moves include better-than-expected results, gained traction, and improved guidance pointing to additional upside.May 10, 2024 | marketbeat.comThese 7 Stocks Surged Double-Digits and Have Double-Digits to Go (TEVA)Stocks surging on earnings reports often continue moving higher over time. This is a look at seven that surged more than 10% on Q1 results.May 9, 2024 | msn.comTeva Pharm to launch Humira biosimilar as Q1 profit misses estimatesMay 9, 2024 | markets.businessinsider.comUBS Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)May 9, 2024 | seekingalpha.comTeva Pharmaceutical: 6 Takeaways From Q1 2024 Earnings ResultsMay 9, 2024 | marketbeat.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Los Angeles Capital Management LLCLos Angeles Capital Management LLC cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 57.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,714 shares of the company's stoMay 9, 2024 | seekingalpha.comTeva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)May 8, 2024 | msn.comTeva, Medincell succeed in late-stage trial for injectable schizophrenia therapyMay 8, 2024 | markets.businessinsider.comTeva Pharmaceutical Industries Posts Narrower Loss In Q1 - UpdateMay 8, 2024 | marketwatch.comTeva Pharma ADRs Climb 12% on 1Q Rev Beat, Schizophrenia Candidate Study ResultsMay 8, 2024 | marketwatch.comTeva Pharmaceutical Industries 1Q Revenue Tops Estimates on Generic Products Sales BoostMay 8, 2024 | marketbeat.comTeva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High at $14.89Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 1-Year High at $14.89May 8, 2024 | marketbeat.comTeva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2024 Earnings GuidanceTeva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2024 earnings guidance. The company provided EPS guidance of 2.200-2.500 for the period, compared to the consensus estimate of 2.410. The company also issued revenue guidance of $15.7 billionillion-$16.3 billionillion, compared to the consensus estimate of $15.9 billionillion.May 8, 2024 | investors.comTeva Surges To 5-Year High On Maintained Outlook Despite Mixed First QuarterMay 8, 2024 | seekingalpha.comTeva Pharmaceutical Industries Limited 2024 Q1 - Results - Earnings Call PresentationMay 8, 2024 | reuters.comTeva Pharm Q1 profit falls short of estimates, revenue gainsMay 8, 2024 | businesswire.comTeva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial OutlookMay 8, 2024 | reuters.comTeva and Medincell's schizophrenia drug meets main goal of late-stage study Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Kiss of death from Joe Biden (Ad)I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care. I have uncovered a bombshell that changes everything… and threatens everything. TEVA Media Mentions By Week TEVA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TEVA News Sentiment▼0.380.76▲Average Medical News Sentiment TEVA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TEVA Articles This Week▼196▲TEVA Articles Average Week Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALNY News GMAB News BGNE News BMRN News VTRS News UTHR News SRPT News RDY News CTLT News ELAN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:TEVA) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
